GSK SEC Filings
NYSE: GSKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
46.50-0.04 (-0.09%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GSK filing overview
This page lists 60 recent SEC filings by GSK (GSK), including 57 6-K, 2 424B2, 1 SCHEDULE 13G/A. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
GSK SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Oct 8, 2026 | 6-K | WENDY BECKER CBE - NEW DIRECTORSHIP | View on EDGAR |
| Oct 6, 2026 | 6-K | ADMISSION TO TRADING | View on EDGAR |
| Oct 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Sep 24, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 22, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 15, 2026 | 6-K | Report of foreign private issuer | View on EDGAR |
| Sep 15, 2026 | 6-K | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | View on EDGAR |
| Sep 14, 2026 | 6-K | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC | View on EDGAR |
| Sep 14, 2026 | 6-K | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA | View on EDGAR |
| Sep 11, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 10, 2026 | 424B2 | Prospectus | View on EDGAR |
| Sep 10, 2026 | 6-K | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE | View on EDGAR |
| Sep 10, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 9, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 9, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 8, 2026 | 6-K | Report of foreign private issuer | View on EDGAR |
| Sep 8, 2026 | 424B2 | Prospectus | View on EDGAR |
| Sep 1, 2026 | 6-K | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III | View on EDGAR |
| Sep 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Aug 26, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 24, 2026 | 6-K | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER | View on EDGAR |
| Aug 24, 2026 | 6-K | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN | View on EDGAR |
| Aug 24, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 18, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 13, 2026 | SCHEDULE 13G/A | Beneficial ownership report (passive) (amendment) | View on EDGAR |
| Aug 13, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 11, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 3, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Jul 30, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 28, 2026 | 6-K | 2ND QUARTER RESULTS | View on EDGAR |
| Jul 28, 2026 | 6-K | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ | View on EDGAR |
| Jul 28, 2026 | 6-K | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE | View on EDGAR |
| Jul 24, 2026 | 6-K | ADMISSION TO TRADING | View on EDGAR |
| Jul 24, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 22, 2026 | 6-K | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS | View on EDGAR |
| Jul 20, 2026 | 6-K | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE | View on EDGAR |
| Jul 17, 2026 | 6-K | CAMLIPIXANT PHASE III RESULTS UPDATE | View on EDGAR |
| Jul 17, 2026 | 6-K | AUDIT TENDER CONCLUSION | View on EDGAR |
| Jul 16, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 15, 2026 | 6-K | GSK COMPLETES ACQUISITION OF NUVALENT, INC | View on EDGAR |
| Jul 14, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 13, 2026 | 6-K | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER | View on EDGAR |
| Jul 13, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 10, 2026 | 6-K | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ | View on EDGAR |
| Jul 9, 2026 | 6-K | DIRECTORATE CHANGE | View on EDGAR |
| Jul 9, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jul 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Jun 29, 2026 | 6-K | HOLDING(S) IN COMPANY | View on EDGAR |
| Jun 29, 2026 | 6-K | TRANSACTION IN OWN SHARES | View on EDGAR |
| Jun 26, 2026 | 6-K | HOLDING(S) IN COMPANY | View on EDGAR |
| Jun 24, 2026 | 6-K | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT | View on EDGAR |
| Jun 24, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jun 23, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jun 22, 2026 | 6-K | TRANSACTION IN OWN SHARES | View on EDGAR |
| Jun 17, 2026 | 6-K | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA | View on EDGAR |
| Jun 15, 2026 | 6-K | TRANSACTION IN OWN SHARES | View on EDGAR |
| Jun 12, 2026 | 6-K | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS | View on EDGAR |
| Jun 11, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jun 10, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Jun 9, 2026 | 6-K | DR HAL BARRON - NEW DIRECTORSHIP | View on EDGAR |